JP6572130B2 - 内皮機能不全及び炎症の疾患の治療 - Google Patents

内皮機能不全及び炎症の疾患の治療 Download PDF

Info

Publication number
JP6572130B2
JP6572130B2 JP2015546770A JP2015546770A JP6572130B2 JP 6572130 B2 JP6572130 B2 JP 6572130B2 JP 2015546770 A JP2015546770 A JP 2015546770A JP 2015546770 A JP2015546770 A JP 2015546770A JP 6572130 B2 JP6572130 B2 JP 6572130B2
Authority
JP
Japan
Prior art keywords
cells
stro
cell
progeny
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015546770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504311A5 (enExample
JP2016504311A (ja
Inventor
グレゴリー キンプトン、ウェイン
グレゴリー キンプトン、ウェイン
リーヴズ ベイリー、サイモン
リーヴズ ベイリー、サイモン
イテシュー、シルビウ
ゴーシュ、ピーター
Original Assignee
メソブラスト、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メソブラスト、インコーポレイテッド filed Critical メソブラスト、インコーポレイテッド
Publication of JP2016504311A publication Critical patent/JP2016504311A/ja
Publication of JP2016504311A5 publication Critical patent/JP2016504311A5/ja
Application granted granted Critical
Publication of JP6572130B2 publication Critical patent/JP6572130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
JP2015546770A 2012-12-12 2013-12-12 内皮機能不全及び炎症の疾患の治療 Active JP6572130B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12
US61/736,361 2012-12-12
PCT/AU2013/001452 WO2014089623A1 (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019123243A Division JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療

Publications (3)

Publication Number Publication Date
JP2016504311A JP2016504311A (ja) 2016-02-12
JP2016504311A5 JP2016504311A5 (enExample) 2017-01-19
JP6572130B2 true JP6572130B2 (ja) 2019-09-04

Family

ID=50933585

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015546770A Active JP6572130B2 (ja) 2012-12-12 2013-12-12 内皮機能不全及び炎症の疾患の治療
JP2019123243A Active JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療
JP2021008250A Active JP7201715B2 (ja) 2012-12-12 2021-01-21 内皮機能不全及び炎症の疾患の治療
JP2022206042A Pending JP2023030116A (ja) 2012-12-12 2022-12-22 内皮機能不全及び炎症の疾患の治療
JP2024111736A Pending JP2024147655A (ja) 2012-12-12 2024-07-11 内皮機能不全及び炎症の疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019123243A Active JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療
JP2021008250A Active JP7201715B2 (ja) 2012-12-12 2021-01-21 内皮機能不全及び炎症の疾患の治療
JP2022206042A Pending JP2023030116A (ja) 2012-12-12 2022-12-22 内皮機能不全及び炎症の疾患の治療
JP2024111736A Pending JP2024147655A (ja) 2012-12-12 2024-07-11 内皮機能不全及び炎症の疾患の治療

Country Status (11)

Country Link
US (2) US20160175360A1 (enExample)
EP (2) EP3556850A1 (enExample)
JP (5) JP6572130B2 (enExample)
KR (3) KR102506612B1 (enExample)
CN (2) CN105358163B (enExample)
AU (4) AU2013360024B2 (enExample)
CA (1) CA2893942C (enExample)
ES (1) ES2742035T3 (enExample)
IL (1) IL239308A0 (enExample)
SG (2) SG11201504340YA (enExample)
WO (1) WO2014089623A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101718375B1 (ko) 2007-12-04 2017-03-22 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
CN105358163B (zh) * 2012-12-12 2020-09-11 麦瑟布莱斯特公司 内皮功能障碍和炎症的疾病的治疗
WO2022114111A1 (ja) * 2020-11-27 2022-06-02 マルホ株式会社 医薬品又は化粧品用組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
ES2239801T3 (es) * 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CN101506355B (zh) 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代（memp）及其应用
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
CA2608048A1 (en) * 2005-05-10 2006-11-16 United States Of America Department Of Veteran's Affairs Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
AU2008334036B2 (en) * 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
EP2227238A2 (en) * 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
KR101718375B1 (ko) * 2007-12-04 2017-03-22 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
ES2550795T3 (es) * 2008-11-20 2015-11-12 Mesoblast, Inc. Método para tratar o prevenir una disfunción pancreática
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) * 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2012047733A2 (en) * 2010-09-29 2012-04-12 Aidan Research And Consulting, Llc. Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
AU2012262675B2 (en) * 2011-06-03 2016-05-19 Mesoblast, Inc Methods of treating or preventing neurological diseases
CA2839341C (en) * 2011-07-04 2020-12-15 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
EP2879682B1 (en) * 2012-08-01 2018-03-21 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
CN105358163B (zh) * 2012-12-12 2020-09-11 麦瑟布莱斯特公司 内皮功能障碍和炎症的疾病的治疗
EP2943069B1 (en) * 2013-01-09 2018-08-15 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Also Published As

Publication number Publication date
JP2023030116A (ja) 2023-03-07
EP2931876A4 (en) 2016-05-25
CN105358163A (zh) 2016-02-24
AU2013360024A1 (en) 2015-07-02
JP7201715B2 (ja) 2023-01-10
AU2024227208A1 (en) 2024-10-31
AU2019202960B2 (en) 2021-07-29
JP2019214571A (ja) 2019-12-19
US20240115618A1 (en) 2024-04-11
EP2931876A1 (en) 2015-10-21
CN111840329B (zh) 2024-10-15
EP3556850A1 (en) 2019-10-23
KR20210021104A (ko) 2021-02-24
HK1210209A1 (en) 2016-04-15
ES2742035T3 (es) 2020-02-12
AU2013360024B2 (en) 2019-02-28
KR20150093732A (ko) 2015-08-18
AU2019202960A1 (en) 2019-05-16
SG11201504340YA (en) 2015-07-30
IL239308A0 (en) 2015-07-30
KR20220029758A (ko) 2022-03-08
US20160175360A1 (en) 2016-06-23
AU2021250848A1 (en) 2021-11-04
EP2931876B1 (en) 2019-05-29
KR102217962B1 (ko) 2021-02-22
JP2016504311A (ja) 2016-02-12
JP2021073240A (ja) 2021-05-13
JP2024147655A (ja) 2024-10-16
CA2893942C (en) 2023-03-28
CA2893942A1 (en) 2014-06-19
JP6829288B2 (ja) 2021-02-10
SG10201705061RA (en) 2017-07-28
CN105358163B (zh) 2020-09-11
KR102506612B1 (ko) 2023-03-06
WO2014089623A1 (en) 2014-06-19
CN111840329A (zh) 2020-10-30
KR102367981B1 (ko) 2022-02-25

Similar Documents

Publication Publication Date Title
JP6505148B2 (ja) 移植片対宿主病の治療法
US20240115618A1 (en) Treatment of diseases of endothelial dysfunction and inflammation
US10159696B2 (en) Methods for treating obesity and/or metabolic syndrome
HK40014520A (en) Treatment of diseases of endothelial dysfunction and inflammation
HK1210209B (en) Treatment of diseases of endothelial dysfunction and inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150810

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190809

R150 Certificate of patent or registration of utility model

Ref document number: 6572130

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250